Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report
Focus keyword: FDA hemp compliance risks 2024
The regulatory landscape for hemp companies in 2024 is more turbulent than ever. With a surge in FDA warning letters and expanding compliance obligations, hemp and CBD businesses must stay sharply attuned to both federal and state requirements to avoid daunting civil and criminal penalties. Below, we analyze the most recent trends, guidance, and enforcement highlights impacting FDA hemp compliance risks 2024—providing essential insights for operators, compliance officers, and investors in the hemp sector.
Hemp and its derivatives—chiefly cannabidiol (CBD)—were removed from the Controlled Substances Act by the 2018 Farm Bill, provided products contain less than 0.3% Delta-9 THC. However, the FDA continues to regulate hemp-derived products under the Food, Drug, and Cosmetic Act (FDCA). This means:
While hemp legalization had initially opened lucrative opportunities, 2024 has seen an escalation in:
The FDA has publicly posted numerous warning letters to hemp and CBD companies in 2024 for violations including unsubstantiated therapeutic claims, misbranding, and adulteration (FDA source). Examples include:
A common thread in these letters is:
Key Takeaway: If you’re marketing hemp-derived products, any hint of disease treatment or prevention in your marketing materials will draw FDA scrutiny.
Labeling & Packaging:
Manufacturing Practices:
Marketing & Claims:
THC Content and Intoxicating Cannabinoids:
Penalties for Non-Compliance
Example: In November 2024, the FDA sent warning letters to at least 15 companies marketing CBD products for conditions such as pain, anxiety, or cancer—prompting some brands to remove affected products or update labeling to address FDA concerns (source).
Multi-Agency Scrutiny
Proactive compliance not only mitigates legal risk but also positions your company as a trusted, sustainable operator.
For operators, continuous monitoring of both FDA and state cannabis and hemp regulations is crucial.
Navigating the rapidly shifting terrain of FDA hemp compliance risks in 2024 demands vigilance, transparency, and commitment to best practices.
For up-to-date rule tracking, compliance guides, and state-by-state breakdowns, visit CannabisRegulations.ai and ensure your business remains ahead of the regulatory curve.
This article is for informational purposes only and does not constitute legal advice. For legal interpretation, consult a licensed attorney with cannabis and FDA regulatory expertise.